Sign In
Buy ABBV
$217.07
+1.64 (+0.761%)
At Close: Jun 03, 2026
AbbVie Revenue Rises on Immunology Growth
08:34am, Wednesday, 04'th Feb 2026
AbbVie posted higher fourth-quarter revenue on the back of growth from its immunology portfolio, led by arthritis and Crohn's disease drugs Skyrizi and Rinvoq.
AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway.
08:18am, Wednesday, 04'th Feb 2026
AbbVie posts better-than-expected earnings but revenue declines across certain business lines.
AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs
07:51am, Wednesday, 04'th Feb 2026
AbbVie forecast 2026 profit above Wall Street estimates on Wednesday after posting a fourth-quarter results beat, fueled by strong demand for newer immunology drugs Skyrizi and Rinvoq and a smaller-th
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
07:48am, Wednesday, 04'th Feb 2026
Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76 Per S
First Look: Lilly jumps; Novo warns; Walmart tops $1T
07:38am, Wednesday, 04'th Feb 2026
Stock News Lilly beats and lifts outlook: Eli Lilly (LLY) posted Q4 revenue of $19.29B (+43%) and adjusted EPS of $7.54, and guided 2026 revenue to $80â$83B a
Market Today: Disney picks D'Amaro; PepsiCo trims prices
05:35pm, Tuesday, 03'rd Feb 2026
Guru Stock PicksT Rowe Price Equity Income Fund has made the following transactions:Reduce in MET by 1.04%Sold out in ADBEAdd in REXR by 1.73%New position in CO
2 Healthcare Dividend Stocks That are Just What the Doctor Ordered
05:35pm, Tuesday, 03'rd Feb 2026
AbbVie has successfully hurdled the Humira patent cliff. Medtronic is seeing new growth from smart devices.
Allergan Aesthetics Continues Its Mission of Empowering Women Through the Faces of Natrelle® Testimonial Program
08:50am, Tuesday, 03'rd Feb 2026
The nationwide program invites eligible Natrelle® breast augmentation and reconstruction patients to share their personal experiences. Natrelle® champions women's voices to provide support at every
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
08:00am, Tuesday, 03'rd Feb 2026
Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement in total body re-pigmentation (T
Buy AbbVie Stock Before Q4 Earnings? Here's What to Know
11:36am, Monday, 02'nd Feb 2026
ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to the industry.
Where Will AbbVie Be in 5 Years?
03:45am, Monday, 02'nd Feb 2026
A prediction for AbbVie in 2031: The drugmaker will be bigger and kinglier.
Wall Street Week Ahead
07:03am, Sunday, 01'st Feb 2026
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
2 No-Brainer Dividend Stocks to Buy Hand Over Fist
05:53am, Sunday, 01'st Feb 2026
AbbVie boasts an impressive streak of dividend growth, and that is unlikely to end anytime soon. Mastercard can support a rapidly growing dividend as it gains ground in a vast addressable market.
Best Dividend Aristocrats For February 2026
04:31am, Saturday, 31'st Jan 2026
Dividend Aristocrats underperformed the S&P 500 in 2025, with NOBL returning 6.82% versus SPY's 17.70%. 2026 began strong for Aristocrats, with NOBL gaining 5.67% in January, outpacing SPY's 1.47%. Di
Better Long-Term Buy: This Emerging Player or the Industry Leader?
03:30pm, Friday, 30'th Jan 2026
AbbVie is a well-established drugmaker with fast-growing immunology products and a solid dividend program. Abivax could challenge pharmaceutical giants like AbbVie in a niche of the immunology market.
